First clinical experience with intravenous recombinant human relaxin in compensated heart failure

Annals of the New York Academy of Sciences

Volumn 1160, Issue , 2009, Pages 387-392

  Dschietzig, Thomas ^a   Teichman, Sam ^b   Unemori, Elaine ^b   Wood, Susy ^b   Boehmer, Julia ^a   Richter, Christoph ^a   Baumann, Gert ^a   Stangl, Karl ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Corthera Inc ^*  (United States)

Author keywords

Heart failure; Hemodynamics; Peptide; Vasodilation

Indexed keywords

RECOMBINANT RELAXIN;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART INDEX; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; LUNG WEDGE PRESSURE; VASODILATATION;

EID: 64549087174     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03819.x     Document Type: Conference Paper

References (11)

1. Allen, L.A. & C.M. O'Connor. 2007. Management of acute decompensated heart failure. CMAJ 176: 797-805.
2. Nieminen, M.S., M. Bohm, M.R. Cowie, Circ. Res. 2005. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26: 384-416.
3. Schrier, R.W. 2006. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J. Am. Coll. Cardiol. 47: 1-8.
4. Dschietzig, T., C. Bartsch, G. Baumann, et al. 2006. Relaxin: Apleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol. Ther. 112: 38-56.
5. Nistri, S., M. Bigazzi & D. Bani. 2007. Relaxin as a cardiovascular hormone: Physiology, pathophysiology and therapeutic promises. Cardiovasc. Hematol. Agents Med. Chem. 5: 101-108.
6. Dschietzig, T., C. Bartsch, C. Richter, Circ. Res. 2003. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: Attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-κB. Circ. Res. 92: 32-40.
7. Jeyabalan, A., J. Novak, L.A. Danielson, et al. 2003. Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ. Res. 93: 1249-1257.
8. Dschietzig, T., C. Richter, C. Bartsch, et al. 2001. The pregnancy hormone relaxin is a player in human heart failure. FASEBJ. 15: 2187-2195.
9. Sackner-Bernstein, J.D., M. Kowalski, M. Fox, et al. 2005. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293: 1900-1905.
10. Debrah, D.O., K.P. Conrad, A. Jeyabalan, et al. 2005. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 46: 745-750.
11. Edouard, D.A., B.M. Pannier, G.M. London, et al. 1998. Venous and arterial behavior during normal pregnancy. Am. J. Physiol. 274: H1605-H1612.